{"product_id":"gild-five-forces","title":"(GILD) Gilead Sciences, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Gilead Sciences, Inc. Porter's Five Forces Analysis helps you assess competitive pressure, market attractiveness, and the forces shaping the company’s position. This page already shows a real preview of the report, so you can review the content before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI and specialty ingredient reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. relies on specialty APIs and biologic inputs for therapies like Biktarvy, Trodelvy, and Yescarta, so suppliers with validated quality systems can keep some leverage. Switching a qualified source can take months and trigger revalidation, regulatory review, and batch-risk costs. That keeps supplier power moderate, especially where Gilead’s 2024 product sales were about $27.8B.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing capacity constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiopharma manufacturing needs GMP-certified facilities, specialist staff, and nonstop quality control, so qualified capacity stays tight. That can lift input costs and slow production if a supplier slips. Gilead Sciences, Inc. has scale to buffer some pressure, but key suppliers still have leverage when capacity is scarce.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers with niche capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. depends on a small set of niche CDMOs for complex products, especially its 2 commercial CAR-T therapies, Yescarta and Tecartus. These cell therapy steps are hard to switch fast, so vendors with the right clean-room and viral-vector capacity can demand better terms when slots are tight. That raises supplier power in parts of the portfolio and can squeeze margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResearch partner dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences, Inc. depends on external research partners to feed its pipeline, so partner leverage is real. In 2024, Gilead reported about $28.8 billion in revenue, and that scale still does not remove the need for licensed assets and platform tech.\u003c\/p\u003e\n\u003cp\u003eWhen a partner brings a strong molecule or a useful platform, it can push for milestone fees, royalties, or tighter control rights. That makes supplier power in innovation sourcing higher than in a normal buying deal. One strong asset can shape terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePipeline access raises partner bargaining power.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMilestones and royalties lift deal cost.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eControl terms can limit Gilead's flexibility.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulated quality standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrict FDA and global GMP rules shrink Gilead Sciences, Inc.'s supplier pool, especially for API, sterile fill-finish, and biologic inputs. For mission-critical materials, a single qualified vendor can take 6-18 months to replace, so once approved, suppliers gain leverage through higher switching costs and continuity risk.\u003c\/p\u003e\n\u003cp\u003eThat matters in a business that still depends on uninterrupted production for high-value therapies: even a short quality hold can delay batch release, raise scrap, and pressure gross margin. The result is stronger supplier power than in lightly regulated industries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew suppliers clear FDA\/EMA checks.\u003c\/li\u003e\n\u003cli\u003eRequalification is slow and costly.\u003c\/li\u003e\n\u003cli\u003eSupply disruption can stop launches.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s Supplier Power Stays Moderate Despite Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. faces moderate supplier power because regulated API, biologic, and CAR-T inputs are hard to replace. With about $27.8B in 2024 product sales and $28.8B in revenue, it has scale, but niche CDMOs and licensed partners still charge up when capacity is tight.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers\u003c\/td\u003e\n\u003ctd\u003eLimited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching time\u003c\/td\u003e\n\u003ctd\u003e6-18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$28.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Gilead Sciences, Inc.’s competition, supplier and buyer power, substitutes, and entry barriers shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick Porter's Five Forces snapshot for Gilead Sciences—clarifies market pressure fast and cuts through strategic noise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Gilead Sciences, Inc., helping decision-makers verify claims quickly and trust the analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBM and payer pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs and insurers hold strong sway over Gilead Sciences, Inc. access and pricing. The top 3 PBMs cover about 80% of U.S. prescriptions, so they can demand rebates and formulary wins on branded drugs. In Gilead Sciences, Inc. 2025 sales of about $28 billion, even small rebate pressure can hit margins fast, so customer power is high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment reimbursement scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic payers heavily constrain Gilead Sciences, Inc.: in 2024 it generated about $28.8 billion in revenue, but a large share of HIV and antiviral demand flows through governments and national health systems. Pricing rules, tenders, and cost-effectiveness reviews can force discounts or delayed access, especially in Europe and other international markets. So customer power stays high, because reimbursement can decide both price and volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and specialty pharmacy concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. sells many therapies through a small set of specialty pharmacies and hospital buyers, so customer power is high. In the U.S., the top 3 pharmacy benefit managers control about 80% of the market, giving intermediaries strong leverage to push preferred therapies and rebates. That scale can steer Gilead volume and pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSwitching across therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn HIV, oncology, and antiviral care, physicians can shift patients among clinically similar therapies, so the customer can press harder on access and net price. Gilead Sciences, Inc. faces that risk most where payers use formulary tiers and prior auth to steer volume.\u003c\/p\u003e\n\u003cp\u003eThat power is real: U.S. HIV treatment has multiple preferred regimens, and even small formulary changes can move large branded sales. For Gilead Sciences, Inc., a rival with better rebates or simpler coverage can win rapid share without changing clinical outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary access drives switching.\u003c\/li\u003e\n\u003cli\u003eNet price can beat brand loyalty.\u003c\/li\u003e\n\u003cli\u003eClinically close drugs raise buyer power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient sensitivity to out-of-pocket cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient cost-sharing still matters in Gilead Sciences, Inc. even when doctors choose the drug. In the U.S., the 2025 Medicare Part D out-of-pocket cap is $2,000, but many commercially insured patients still face copays that can steer them to cheaper options.\u003c\/p\u003e\n\u003cp\u003eThat makes price a real lever on adherence and brand choice, especially where generics exist. So customer bargaining power stays moderate to high, because higher out-of-pocket costs can shift demand away from premium branded therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCopays can reduce adherence.\u003c\/li\u003e\n\u003cli\u003eCheaper alternatives gain share.\u003c\/li\u003e\n\u003cli\u003eGenerics strengthen buyer power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Faces High Buyer Power as PBMs Drive Pricing Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer bargaining power is high for Gilead Sciences, Inc. because payers and PBMs control access and net price. The top 3 U.S. PBMs cover about 80% of prescriptions, and Gilead Sciences, Inc. had about $28.8 billion in 2024 revenue and about $28 billion in 2025 sales, so rebate pressure can hit hard.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 PBMs\u003c\/td\u003e\n\u003ctd\u003eAbout 80% U.S. prescriptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D cap\u003c\/td\u003e\n\u003ctd\u003e$2,000 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePublic payers, specialty pharmacies, and formularies also steer volume, while clinically similar HIV and antiviral options make switching easier. That keeps buyer power high.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGilead Sciences, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Gilead Sciences, Inc. Porter's Five Forces Analysis you'll receive after purchase—no edits, no placeholders, no surprises. It’s the same professionally written document, ready to download and use immediately. What you see here is the final version, so you can buy with confidence knowing the full file will match this preview exactly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense HIV franchise competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. faces intense HIV rivalry because the franchise is a core profit pool, with HIV product sales near $18 billion in FY2024 and Biktarvy around $13 billion. ViiV Healthcare and other rivals fight on efficacy, safety, once-daily dosing, and payer access, with ViiV’s HIV sales above $5 billion in 2024. That makes share gains hard and keeps pricing pressure high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and cell therapy competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompetition in oncology and cell therapy is fierce: Gilead Sciences, Inc.’s Yescarta and Tecartus face fast-moving rivals in CAR-T, bispecifics, and combo regimens. Yescarta and Tecartus generated over $2B in combined 2024 sales, but rapid launch cycles and new modalities keep pressure high. When approvals move in months, not years, rivalry stays intense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature antiviral markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. faces stronger rivalry in mature antiviral and liver disease markets because growth is slower and pricing pressure is higher. In FY2024, Gilead Sciences, Inc. reported $28.8 billion in revenue, with HIV products still the core engine, so rivals keep pressing for share in a crowded field. Even with strong brands like Biktarvy, flat volume trends make competition more about price and switching than new demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline race and patent timing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharma rivalry is a pipeline race, not just a sales fight. Gilead Sciences, Inc. has to defend its HIV cash engine while rivals push new launches and label expansions, because one late patent move can shift share fast. In FY2025, that pressure stays high as every major patent date can redraw the market.\u003c\/p\u003e\n\u003cp\u003eThat means Gilead Sciences, Inc. must keep spending on R\u0026amp;D and lifecycle management to protect future revenue, not only current sales. One clean rule: if the pipeline slows, rivals win ground.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePipeline depth drives future share.\u003c\/li\u003e\n\u003cli\u003ePatent timing can move sales quickly.\u003c\/li\u003e\n\u003cli\u003eLabel expansions can blunt rivals.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend is a defense cost.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal scale competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences faces strong rivalry from global drugmakers like Pfizer, Roche, and Johnson \u0026amp; Johnson, each with R and D spend above $10 billion and sales reach in 100+ markets. Their scale lets them compete in HIV, oncology, liver, and inflammation, while deep payer ties pressure pricing and share. Rivalry stays high because these firms can fund late-stage trials, launch fast, and defend key accounts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig R and D budgets widen the threat.\u003c\/li\u003e\n\u003cli\u003eGlobal sales networks speed market entry.\u003c\/li\u003e\n\u003cli\u003ePayer links weaken Gilead pricing power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Faces Fierce HIV and Oncology Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry for Gilead Sciences, Inc. stays high because HIV is a large, crowded profit pool: FY2024 HIV product sales were about $18 billion, led by Biktarvy at roughly $13 billion. ViiV Healthcare had HIV sales above $5 billion in 2024, so price, access, and switching pressure stay heavy. Oncology and cell therapy add more rivalry as fast launches keep the pipeline race tight.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilead Sciences, Inc. FY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$28.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV product sales\u003c\/td\u003e\n\u003ctd\u003e~$18B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy sales\u003c\/td\u003e\n\u003ctd\u003e~$13B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViiV Healthcare HIV sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric and biosimilar erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhen exclusivity ends, low-cost generics or biosimilars can replace Gilead Sciences, Inc. branded drugs fast, and the hit is sharp in mature areas like HIV and hepatitis C. In 2025, that risk still matters because a single big brand can drive billions in sales, so even small share loss can cut revenue and gross margin hard. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative treatment regimens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlternative regimens are a real threat for Gilead Sciences, Inc. because physicians can switch to rival branded HIV or hepatitis therapies with similar outcomes, especially when payer rules or dosing convenience change. In HIV, long-acting options and fixed-dose combos can quickly pull share away from one drug to another. That matters when HIV still affects about 39 million people worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-drug care options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-drug care can cap Gilead Sciences, Inc.’s usage growth in some indications: for HIV, PrEP, testing, and condom use lower new infections, and for liver disease, monitoring plus lifestyle change can delay drug use. In the U.S., about 1.2 million people live with HIV, so prevention still matters a lot, but it does not replace treatment for most patients.\u003c\/p\u003e\n\u003cp\u003eThe threat is highest where care is preventive or supportive, and lower where drug therapy is standard, like chronic HIV and many cancers. Procedure-based options and watchful waiting can also reduce volume in select cases, but they rarely displace Gilead Sciences, Inc.’s core therapies at scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-generation modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNext-generation modalities raise substitute risk for Gilead Sciences, Inc. because longer-acting injectables, cell and gene therapies, and targeted immunotherapies can replace chronic pills and older biologics. When one dose lasts months instead of daily use, uptake can speed fast, especially in HIV and oncology where adherence and convenience drive choice.\u003c\/p\u003e\n\u003cp\u003eThat pressure is real: Gilead Sciences, Inc. already has approved cell therapies in market, and rivals keep pushing longer-durability options that can cut treatment burden. If a new therapy offers fewer visits, better persistence, or deeper response, payers and doctors can switch quickly.\u003c\/p\u003e\n\u003cp\u003eThe threat is strongest in high-value niches where Gilead Sciences, Inc. depends on repeat use, because a single curative or ultra-long-acting product can shrink lifetime revenue per patient. In plain terms, better dosing can beat brand strength.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLonger dosing cuts switching barriers\u003c\/li\u003e\n\u003cli\u003eCell and gene therapies can displace chronic drugs\u003c\/li\u003e\n\u003cli\u003eBetter durability speeds adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTherapeutic guideline shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapeutic guideline shifts can lift substitution for Gilead Sciences, Inc. even without a price fight, because doctors may move to other classes or delivery methods. In HIV, 39.9 million people were living with the disease in 2023, and long-acting injectables and newer regimens keep changing practice patterns. That makes the threat moderate to high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGuidelines can favor new classes\u003c\/li\u003e\n\u003cli\u003eSwitches can bypass price cuts\u003c\/li\u003e\n\u003cli\u003eInjectables raise substitution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Faces Moderate-to-High Substitute Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Gilead Sciences, Inc. is moderate to high because HIV and hepatitis C patients can switch to rival branded regimens, and post-patent generics can replace branded sales fast. Longer-acting injectables, cell therapies, and prevention tools also reduce use of daily pills. In HIV, about 39.9 million people were living with the disease in 2023, so regimen choice still matters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric or biosimilar drugs\u003c\/td\u003e\n\u003ctd\u003eHigh after exclusivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-acting injectables\u003c\/td\u003e\n\u003ctd\u003eHigh in HIV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevention and monitoring\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeavy regulatory barriers keep new entrants out because a drug must clear preclinical testing, phased clinical trials, and FDA review, a path that often takes 10–15 years and can cost over $1 billion. In 2024, the FDA approved 50 new drugs, showing how selective the gate is. With high failure risk and long payback periods, Gilead Sciences, Inc. faces far less threat from new firms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMassive capital requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunching a biopharmaceutical company takes huge cash for R and D, manufacturing, safety monitoring, and sales. New drug development can cost over $2 billion and take 10-15 years, so few entrants can fund the pipeline without partners or outside capital. That cost wall strongly limits new competition for Gilead Sciences, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. had about $28.8 billion in 2024 revenue, and much of that rests on patent-protected drugs and platforms. New entrants must work around Gilead Sciences, Inc. patents or wait for expiry, which raises R\u0026amp;D cost, time, and legal risk. That barrier is high in HIV and antiviral markets, where one product can face layered IP claims and long launch delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialized manufacturing know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized manufacturing know-how keeps the threat of new entrants low for Gilead Sciences, Inc. Advanced biologics and cell therapies need validated processes, clean-room capacity, and strict FDA\/EMA compliance, and building that from scratch can take years and hundreds of millions of dollars. That delay and cost make entry hard, even before a new rival can ship one dose.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValidated expertise is hard to copy.\u003c\/li\u003e\n\u003cli\u003eCompliant plants take years to build.\u003c\/li\u003e\n\u003cli\u003eHigh capex blocks fast market entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership-based entry paths\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmaller biotechs can still enter Gilead Sciences, Inc.’s orbit by building platform science and partnering with larger drugmakers, which cuts the need for a full sales, supply, and regulatory stack. Gilead Sciences, Inc. has spent about $4.4 billion a year on R\u0026amp;D and posted roughly $28.6 billion in 2024 revenue, so its scale still sets a high bar. That makes the threat limited, but not zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePartnerships lower launch costs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePlatform science speeds entry.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eScale still blocks many startups.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eThreat stays limited, not zero.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s New Entrants Barrier Remains Tough to Break\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Gilead Sciences, Inc. stays low because FDA review, long trials, and patent walls make entry slow and costly. Biopharma launches often need over $1 billion and 10–15 years, while Gilead Sciences, Inc. still generated about $28.8 billion in 2024 revenue and spent about $4.4 billion on R\u0026amp;D, which raises the bar further. Partnerships can help small biotechs enter, but they still lack scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulation\u003c\/td\u003e\n\u003ctd\u003e10–15 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e$28.8B revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$4.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191757611273,"sku":"gild-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gild-five-forces.webp?v=1783676753","url":"https:\/\/dcfanalyst.com\/products\/gild-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}